|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
41,504,000 |
Market
Cap: |
1.32(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$21.16 - $40.91 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 625 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
181,711 |
289,391 |
332,975 |
1,049,160 |
Total Sell Value |
$6,087,407 |
$9,456,240 |
$10,506,887 |
$26,725,036 |
Total People Sold |
4 |
6 |
6 |
7 |
Total Sell Transactions |
5 |
12 |
14 |
44 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Santini Gino |
Director |
|
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
9,941 |
44,136 |
|
- |
|
Melincoff Gwen A |
Director |
|
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
9,941 |
20,948 |
|
- |
|
Heffernan Michael Thomas |
Director |
|
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
9,941 |
13,988 |
|
- |
|
Freund John Gordon |
Director |
|
2021-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
9,941 |
20,948 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2021-05-10 |
4 |
AS |
$22.77 |
$159,390 |
D/D |
(7,000) |
89,990 |
|
-10% |
|
Fleming Alison B |
Chief Technical Officer |
|
2021-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,984 |
154,737 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2021-03-16 |
4 |
D |
$24.69 |
$18,122 |
D/D |
(734) |
96,990 |
|
- |
|
Heffernan Michael Thomas |
Director |
|
2021-03-15 |
4 |
AS |
$25.26 |
$1,266,774 |
D/D |
(50,075) |
4,047 |
|
1% |
|
Ciaffoni Joseph |
President and CEO |
|
2021-03-01 |
4 |
AS |
$22.56 |
$1,468,425 |
D/D |
(64,768) |
278,307 |
|
-2% |
|
Ciaffoni Joseph |
President and CEO |
|
2021-03-01 |
4 |
OE |
$8.22 |
$399,624 |
D/D |
48,616 |
343,075 |
|
- |
|
Fleming Alison B |
Chief Technical Officer |
|
2021-03-01 |
4 |
AS |
$23.36 |
$140,417 |
D/D |
(6,011) |
148,753 |
|
-2% |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2021-02-11 |
4 |
AS |
$24.89 |
$199,132 |
D/D |
(7,898) |
83,258 |
|
-6% |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2021-02-10 |
4 |
D |
$25.95 |
$152,015 |
D/D |
(5,858) |
97,724 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2021-02-10 |
4 |
D |
$25.95 |
$617,247 |
D/D |
(23,786) |
294,459 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2021-02-10 |
4 |
D |
$25.95 |
$134,525 |
D/D |
(5,184) |
91,156 |
|
- |
|
Malamut Richard |
EVP and Chief Medical Officer |
|
2021-02-10 |
4 |
D |
$25.95 |
$59,685 |
D/D |
(2,300) |
96,677 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2021-02-10 |
4 |
D |
$25.95 |
$220,341 |
D/D |
(8,491) |
215,428 |
|
- |
|
Fleming Alison B |
Chief Technical Officer |
|
2021-02-10 |
4 |
D |
$25.95 |
$185,387 |
D/D |
(7,144) |
156,164 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2021-01-20 |
4 |
AS |
$24.45 |
$148,680 |
D/D |
(6,081) |
103,582 |
|
-1% |
|
Fleming Alison B |
Chief Technology Officer |
|
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
51,889 |
163,308 |
|
- |
|
Ciaffoni Joseph |
President and CEO |
|
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
133,989 |
318,245 |
|
- |
|
Malamut Richard |
EVP and Chief Medical Officer |
|
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
39,147 |
98,977 |
|
- |
|
Dreyer Scott |
EVP & Chief Commercial Officer |
|
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
51,945 |
96,340 |
|
- |
|
Brannelly Paul |
Executive Vice President & CFO |
|
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
50,161 |
223,919 |
|
- |
|
Kuhlmann Shirley R. |
EVP and General Counsel |
|
2021-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
52,132 |
109,663 |
|
- |
|
391 Records found
|
|
Page 6 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|